If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,804.00    -100.00 (-3.44%)
Bid:
2,760.00
Ask:
2,766.00
Spread: 6.00 (0.217%)
Market Cap: £1.54b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Acquisition

17 Dec 2012 07:00

RNS Number : 6368T
Oxford Instruments PLC
17 December 2012
 



Embargoed until 7am, 17 December 2012

 

Oxford Instruments plc: Acquisition of Asylum Research Corp.

 

Oxford Instruments plc ("Oxford Instruments" or "the Group"), a leading provider of high technology tools and systems for industry and research, announces the acquisition of Asylum Research Corporation ("Asylum Research"), a leading provider of Scanning Probe Microscopes (SPM). The acquisition is subject to customary conditions and is expected to be completed before the end of December 2012.

 

Asylum Research is an established US company based in Santa Barbara, California, with subsidiaries in the UK, Germany and Taiwan. Its SPM technology is used to image and characterise the properties of surfaces and structures down to the atomic scale providing invaluable information to enable development and exploitation at the nanoscale. Its products are used by academic and industrial customers across the world for a wide range of materials and bioscience applications. The combination of Oxford Instruments and Asylum Research strengthens the Group's Nanotechnology Tools sector. SPM is a fundamental nanotechnology measurement technique and complements the existing portfolio of products and technologies within the Group.

 

Asylum Research is being acquired from its management for an initial debt free, cash free consideration of US$32.0 million with a deferred element of up to US$48.0 million payable over three years dependent on its performance over that period. Asylum Research generated Earnings Before Interest and Taxation (EBIT) of $1.1 million in the twelve months to 31 December 2011 from revenue in the same period of $19.6 million. It had gross assets of $6.2 million as at 31 December 2011. The acquisition will be funded from existing facilities.

 

The acquisition of Asylum Research is in line with Oxford Instruments' 14 Cubed objectives, to achieve a 14% average compound annual growth rate in revenues and a 14% return on sales by the year ending March 2014. This acquisition contributes to the planned acquisition element of the revenue growth objective. While Asylum Research is expected to deliver less than the 14% targeted margin in this and the next financial year, following the acquisition the 14 Cubed margin target for the Group remains unchanged.

 

As part of Oxford Instruments there will be significant scope to accelerate the inherent strong growth of Asylum Research's end markets and to deliver substantial improvements in margin over time based on increasing scale. Approximately 60% of Asylum Research turnover comes from customers working in the materials science area where the customer base and routes to market are shared with Oxford Instruments. This opens opportunities for market synergies and the development of new integrated products. The remainder of Asylum Research's turnover is in the bio-nano area where SPM instruments are used for research into soft materials, such as DNA. This market provides a new growth opportunity for Oxford Instruments.

 

 Commenting on the acquisition, Jonathan Flint, Chief Executive of Oxford Instruments, stated:

 

"The acquisition of Asylum Research significantly increases our footprint in the nanotechnology space and complements our strong position in electron microscopes with a presence in another fundamental nanotechnology measurement technique. The acquisition also gives us access to the rapidly growing bio-nano market as it allows customers to perform analysis of organic samples in their natural liquid environments, something which cannot readily be done using electron microscopes."

 

A conference call for analysts and investors will be held at 08.30 (UK time) today to discuss this statement.

 

Participant Access Details:

Toll Number +44 203 139 4830

Toll-Free Number 0808 237 0030

Participant PIN Code 81210256#

 

- Ends -

 

Issued for and on behalf of Oxford Instruments plc

For further information please contact:

 

Oxford Instruments Plc

+44 (0)1865 393200

Jonathan Flint, Chief Executive

Kevin Boyd, Group Finance Director

 

MHP Communications

Rachel Hirst

Ian Payne

 

 

 

 

+44 (0) 20 3128 8100

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. It provides solutions needed to advance fundamental physics research and its transfer into commercial nanotechnology applications. Innovation has been the driving force behind Oxford Instruments' growth and success for over 50 years, and its strategy is to effect the successful commercialisation of these ideas by bringing them to market in a timely and customer-focused fashion. 

The first technology business to be spun out from Oxford University over fifty years ago, Oxford Instruments is now a global company with over 2000 staff worldwide and is listed on the FTSE250 index of the London Stock Exchange (OXIG).  Its objective is to be the leading provider of new generation tools and systems for the research and industrial sectors.

This involves the combination of core technologies in areas such as low temperature, high magnetic field and ultra high vacuum environments, Nuclear Magnetic Resonance, X-ray, electron and optical based metrology, and advanced growth, deposition and etching.

Oxford Instruments aims to pursue responsible development and deeper understanding of our world through science and technology. Its products, expertise, and ideas address global issues such as energy, environment, security and health.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEADAKFAPAFAF
Date   Source Headline
30th Mar 20207:00 amRNSSuspension of Interim Dividend
20th Mar 202012:07 pmRNSSecond Price Monitoring Extn
20th Mar 202012:02 pmRNSPrice Monitoring Extension
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:36 pmRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSTrading Update
12th Mar 202011:11 amPRNDirector/PDMR Shareholding
4th Mar 202010:02 amPRNAppointment of External Auditor
2nd Mar 202012:06 pmPRNTotal Voting Rights
2nd Mar 202012:02 pmRNSPrice Monitoring Extension
27th Feb 202012:07 pmRNSSecond Price Monitoring Extn
27th Feb 202012:02 pmRNSPrice Monitoring Extension
24th Feb 20207:00 amRNSDisposal of OI Healthcare business in the US
10th Feb 20201:49 pmPRNDirector/PDMR Shareholding
3rd Feb 202012:41 pmPRNTotal Voting Rights
29th Jan 20207:00 amRNSSale of Minority Share in Scienta Omicron
23rd Jan 202010:52 amPRNAdditional Listing
13th Jan 20209:55 amPRNDirector/PDMR Shareholding
10th Jan 202012:02 pmRNSPrice Monitoring Extension
9th Jan 202010:42 amPRNTotal Voting Rights
9th Jan 20209:41 amPRNBlocklisting - Interim Review
3rd Jan 20208:36 amPRNHolding(s) in Company
11th Dec 20194:03 pmPRNDirector/PDMR Shareholding
2nd Dec 20192:54 pmPRNTotal Voting Rights
12th Nov 201912:49 pmPRNDirector/PDMR Shareholding
12th Nov 20197:00 amRNSHalf-year Report
11th Oct 201912:02 pmRNSPrice Monitoring Extension
10th Oct 20194:34 pmPRNDirector/PDMR Shareholding
3rd Oct 201911:00 amPRNTotal Voting Rights
11th Sep 20193:30 pmPRNDirector/PDMR Shareholding
11th Sep 201912:12 pmPRNResult of AGM
11th Sep 201910:50 amPRNDirector/PDMR Shareholding
10th Sep 20197:00 amRNSChairman's AGM Statement 2019
29th Aug 201912:07 pmRNSSecond Price Monitoring Extn
29th Aug 201912:02 pmRNSPrice Monitoring Extension
22nd Aug 20191:24 pmPRNHolding(s) in Company
13th Aug 201910:26 amPRNDirector/PDMR Shareholding
15th Jul 20194:26 pmPRNDirector/PDMR Shareholding
11th Jul 201911:49 amPRNDirector/PDMR Shareholding
1st Jul 201911:07 amPRNBlocklisting - Interim Review
27th Jun 20195:01 pmPRNHolding(s) in Company
26th Jun 20195:30 pmRNSRPC Group
11th Jun 20191:02 pmPRNDirector/PDMR Shareholding
11th Jun 20197:00 amRNSFinal Results
30th May 20191:18 pmPRNHolding(s) in Company
13th May 201910:27 amPRNDirector/PDMR Shareholding
11th Apr 201912:00 pmPRNDirector/PDMR Shareholding
11th Apr 20197:00 amRNSTrading Statement
22nd Mar 20197:00 amRNSContract win
11th Mar 20191:40 pmPRNDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.